---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-032004"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T05:59:51.018324+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Director resigns; SEC concludes investigation with no enforcement action

## Summary
- Ankit Mahadevia, MD resigned from board effective Jan 30, 2026 due to other professional commitments; no dispute with company.
- Company intends to enter consulting agreement with Mahadevia for continued support.
- SEC concluded its investigation on Jan 20, 2026; will not recommend enforcement action against company at this time.
- Investigation was previously disclosed in SEC periodic reports.

## SEC filing metadata
- accession: 0001193125-26-032004
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312526032004/0001193125-26-032004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312526032004/d55903d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-032004
- JSON: https://secwatch.observer/filing/0001193125-26-032004.json
- Plain text: https://secwatch.observer/filing/0001193125-26-032004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.